Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease

Objective: Inflammatory bowel disease comprises a group of chronic relapsing inflammatory disorders affecting the bowel. In the last decade, the advent of biological drugs brought about a drastic change in the treatment of the disease. Adalimumab, golimumab and ustekinumab are three biologic agents...

Full description

Saved in:
Bibliographic Details
Main Authors: María Calvo-Arbeloa (Author), Ana María Insausti-Serrano (Author), Amaya Arrondo-Velasco (Author), María Teresa Sarobe-Carricas (Author)
Format: Book
Published: Elsevier, 2020-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available